1 Ocak 2020 Dergi makalesi Açık Erişim

Reeder, Sophia M.; Reuschel, Emma L.; Bah, Mamadou A.; Yun, Kun; Tursi, Nicholas J.; Kim, Kevin Y.; Chu, Jacqueline; Zaidi, Faraz, I; Yilmaz, Ilknur; Hart, Robert J.; Perrin, Benjamin; Xu, Ziyang; Humeau, Laurent; Weiner, David B.; Aly, Ahmed S., I

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Reeder, Sophia M.</dc:creator>
  <dc:creator>Reuschel, Emma L.</dc:creator>
  <dc:creator>Bah, Mamadou A.</dc:creator>
  <dc:creator>Yun, Kun</dc:creator>
  <dc:creator>Tursi, Nicholas J.</dc:creator>
  <dc:creator>Kim, Kevin Y.</dc:creator>
  <dc:creator>Chu, Jacqueline</dc:creator>
  <dc:creator>Zaidi, Faraz, I</dc:creator>
  <dc:creator>Yilmaz, Ilknur</dc:creator>
  <dc:creator>Hart, Robert J.</dc:creator>
  <dc:creator>Perrin, Benjamin</dc:creator>
  <dc:creator>Xu, Ziyang</dc:creator>
  <dc:creator>Humeau, Laurent</dc:creator>
  <dc:creator>Weiner, David B.</dc:creator>
  <dc:creator>Aly, Ahmed S., I</dc:creator>
  <dc:date>2020-01-01</dc:date>
  <dc:description>The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human challenge experiments. To further evaluate protection mediated by LS antigens, we focused on exported pre-erythrocytic proteins (exported protein 1 (EXP1), profilin (PFN), exported protein 2 (EXP2), inhibitor of cysteine proteases (ICP), transmembrane protein 21 (TMP21), and upregulated in infective sporozoites-3 (UIS3)) expressed in all Plasmodium species and designed optimized, synthetic DNA (synDNA) immunogens. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%-88% in non-adjuvanted groups were protected from blood-stage disease following Plasmodium yoelii sporozoite challenge. This study supports the potential of synDNA LS antigens as vaccine components for malaria parasite infection.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/10305</dc:identifier>
  <dc:identifier>oai:zenodo.org:10305</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>VACCINES 8(1)</dc:source>
  <dc:title>Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>